%0 Journal Article %A Cliff C. Kerr %A Dina Mistry %A Robyn M. Stuart %A Katherine Rosenfeld %A Gregory R. Hart %A Rafael C. Núñez %A Jamie A. Cohen %A Prashanth Selvaraj %A Romesh G. Abeysuriya %A Michał Jastrzębski %A Lauren George %A Brittany Hagedorn %A Jasmina Panovska-Griffiths %A Meaghan Fagalde %A Jeffrey Duchin %A Michael Famulare %A Daniel J. Klein %T Controlling COVID-19 via test-trace-quarantine %D 2021 %R 10.1101/2020.07.15.20154765 %J medRxiv %P 2020.07.15.20154765 %X Initial COVID-19 containment in the United States focused on limiting mobility, including school and workplace closures. However, these interventions have had enormous societal and economic costs. Here we demonstrate the feasibility of an alternative control strategy, test-trace-quarantine: routine testing of primarily symptomatic individuals, tracing and testing their known contacts, and placing their contacts in quarantine. We performed this analysis using Covasim, an open-source agent-based model, which was calibrated to detailed demographic, mobility, and epidemiological data for the Seattle region from January through June 2020. With current levels of mask use and schools remaining closed, we found that high but achievable levels of testing and tracing are sufficient to maintain epidemic control even under a return to full workplace and community mobility and with low vaccine coverage. The easing of mobility restrictions in June 2020 and subsequent scale-up of testing and tracing programs through September provided real-world validation of our predictions. Although we show that test-trace-quarantine can control the epidemic in both theory and practice, its success is contingent on high testing and tracing rates, high quarantine compliance, relatively short testing and tracing delays, and moderate to high mask use. Thus, in order for test-trace-quarantine to control transmission with a return to high mobility, strong performance in all aspects of the program is required.Competing Interest StatementThe authors have declared no competing interest.Funding StatementFunding was provided by the Bill and Melinda Gates Foundation. Institutional support, including high-performance computing resources and library access, was provided by the Burnet Institute and the University of Sydney School of Physics.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:N/AAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe Covasim model code is fully open source and available via GitHub: https://github.com/institutefordiseasemodeling/covasim Epidemiological data used in this study are available from the King County Data Dashboard: https://www.kingcounty.gov/depts/health/covid-19/data.aspx SafeGraph mobility data are available from: https://www.safegraph.com/data-examples/covid19-commerce-patterns https://github.com/institutefordiseasemodeling/covasim https://www.kingcounty.gov/depts/health/covid-19/data.aspx https://www.safegraph.com/data-examples/covid19-commerce-patterns https://github.com/amath-idm/controlling-covid19-ttq %U https://www.medrxiv.org/content/medrxiv/early/2021/03/22/2020.07.15.20154765.full.pdf